Drug profile · INN
tixagevimab
EVUSHELD
tixagevimab (EVUSHELD) is a spike glycoprotein blocker.
EMA: withdrawn
Patents linked 0
Pipeline programs 2
News articles 0
Congress events 1
Drug details — tixagevimab
- Class
- —
- Route
- —
- Patents
- 0
- Programs
- 2
- Data quality
- 0.83
Quick answer
tixagevimab (EVUSHELD) is a spike glycoprotein blocker.
Key facts
INN tixagevimab
Brand EVUSHELD
Mechanism Spike glycoprotein blocker
Target Spike glycoprotein
Mechanism of action
Spike glycoprotein blocker
Primary target: Spike glycoprotein
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | withdrawn | — |
Congress & event coverage
- PresentationTHMA Pharmacy Growth
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is tixagevimab?
tixagevimab (EVUSHELD) is a spike glycoprotein blocker.
What is the brand name for tixagevimab?
EVUSHELD is a marketed brand name for tixagevimab. Check FDA Drugs@FDA for the current US label holder and prescribing information.